Troglitazone

Troglitazone (brand name Rezulin) is an anti-diabetic drug in the glitazones class.

Troglitazone was taken off the market in 2000 due to an increased incidence of drug-induced hepatitis in patients who were using the drug. It is now common practice that liver enzymes are monitored during the first year of treatment with the "newer" thiazolidinediones.